Literature DB >> 19846878

Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation.

Kimberly E Barnholt1, Rama S Kota, Hnin Hnin Aung, John C Rutledge.   

Abstract

Macrophages are activated by IFN-gamma, a proinflammatory and proatherogenic cytokine that mediates its downstream effects primarily through STAT1. IFN-gamma signaling induces phosphorylation of two STAT1 residues: Tyr(701) (Y701), which facilitates dimerization, nuclear translocation, and DNA binding; and Ser(727) (S727), which enables maximal STAT1 transcription activity. Immunosuppressive molecules such as adenosine in the cellular microenvironment can reduce macrophage inflammatory and atherogenic functions through receptor-mediated signaling pathways. We hypothesized that adenosine achieves these protective effects by interrupting IFN-gamma signaling in activated macrophages. This investigation demonstrates that adding adenosine to IFN-gamma-stimulated murine RAW 264.7 and human THP-1 macrophages results in unique modulation of STAT1 serine and tyrosine phosphorylation events. We show that adenosine inhibits IFN-gamma-induced STAT1 S727 phosphorylation by >30% and phosphoserine-mediated transcriptional activity by 58% but has no effect on phosphorylation of Y701 or receptor-associated JAK tyrosine kinases. Inhibition of the adenosine A(3) receptor with a subtype-specific antagonist (MRS 1191 in RAW 264.7 cells and MRS 1220 in THP-1 cells) reverses this adenosine suppressive effect on STAT1 phosphoserine status by 25-50%. Further, RAW 264.7 A(3) receptor stimulation with Cl-IB-MECA reduces IFN-gamma-induced STAT1 transcriptional activity by 45% and STAT1-dependent gene expression by up to 80%. These data suggest that A(3) receptor signaling is key to adenosine-mediated STAT1 modulation and anti-inflammatory action in IFN-gamma-activated mouse and human macrophages. Because STAT1 plays a key role in IFN-gamma-induced inflammation and foam cell transformation, a better understanding of the mechanisms underlying STAT1 deactivation by adenosine may improve preventative and therapeutic approaches to vascular disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19846878      PMCID: PMC2916018          DOI: 10.4049/jimmunol.0900331

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

Review 1.  The inflamed plaque: cytokine production and cellular cholesterol balance in the vessel wall.

Authors:  S Fazio; M F Linton
Journal:  Am J Cardiol       Date:  2001-07-19       Impact factor: 2.778

2.  Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms.

Authors:  G Haskó; D G Kuhel; J F Chen; M A Schwarzschild; E A Deitch; J G Mabley; A Marton; C Szabó
Journal:  FASEB J       Date:  2000-10       Impact factor: 5.191

3.  Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression.

Authors:  H Nguyen; C V Ramana; J Bayes; G R Stark
Journal:  J Biol Chem       Date:  2001-07-03       Impact factor: 5.157

4.  Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway.

Authors:  P Kovarik; D Stoiber; P A Eyers; R Menghini; A Neininger; M Gaestel; P Cohen; T Decker
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

5.  Interferon-gamma-mediated downregulation of cholesterol efflux and ABC1 expression is by the Stat1 pathway.

Authors:  Xue-Qing Wang; Constantinos G Panousis; M Leticia Alfaro; Glenn F Evans; Steven H Zuckerman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-05-01       Impact factor: 8.311

Review 6.  Serine phosphorylation of STATs.

Authors:  T Decker; P Kovarik
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

Review 7.  Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling.

Authors:  Chilakamarti V Ramana; M Pilar Gil; Robert D Schreiber; George R Stark
Journal:  Trends Immunol       Date:  2002-02       Impact factor: 16.687

8.  Requirement of Ca2+ and CaMKII for Stat1 Ser-727 phosphorylation in response to IFN-gamma.

Authors:  Jayasree S Nair; Christopher J DaFonseca; Agneta Tjernberg; Wei Sun; James E Darnell; Brian T Chait; J Jillian Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-23       Impact factor: 11.205

Review 9.  Adenosine: a potential mediator of immunosuppression in multiple organ failure.

Authors:  György Haskó; Edwin A Deitch; Csaba Szabó; Zoltán H Németh; E Sylvester Vizi
Journal:  Curr Opin Pharmacol       Date:  2002-08       Impact factor: 5.547

10.  Activation of the adenosine-A3 receptor stimulates matrix metalloproteinase-9 secretion by macrophages.

Authors:  Emilie Velot; Benjamin Haas; Frédérique Léonard; Isabelle Ernens; Magali Rolland-Turner; Chantal Schwartz; Dan Longrois; Yvan Devaux; Daniel R Wagner
Journal:  Cardiovasc Res       Date:  2008-07-24       Impact factor: 10.787

View more
  22 in total

1.  Role of STAT1 and Oxidative Stress in Gentamicin-Induced Hair Cell Death in Organ of Corti.

Authors:  Peng Jiang; Amrita Ray; Leonard P Rybak; Michael J Brenner
Journal:  Otol Neurotol       Date:  2016-10       Impact factor: 2.311

Review 2.  Regulation of foam cells by adenosine.

Authors:  Allison B Reiss; Bruce N Cronstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

Review 3.  Regulation of macrophage function by adenosine.

Authors:  György Haskó; Pál Pacher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

Review 4.  Investigational A₃ adenosine receptor targeting agents.

Authors:  Balázs Koscsó; Balázs Csóka; Pál Pacher; György Haskó
Journal:  Expert Opin Investig Drugs       Date:  2011-04-02       Impact factor: 6.206

Review 5.  A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.

Authors:  Kenneth A Jacobson; Stefania Merighi; Katia Varani; Pier Andrea Borea; Stefania Baraldi; Mojgan Aghazadeh Tabrizi; Romeo Romagnoli; Pier Giovanni Baraldi; Antonella Ciancetta; Dilip K Tosh; Zhan-Guo Gao; Stefania Gessi
Journal:  Med Res Rev       Date:  2017-07-06       Impact factor: 12.944

Review 6.  Could interferon-gamma be a therapeutic target for treating heart failure?

Authors:  Scott P Levick; Paul H Goldspink
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

7.  Macrophage A2A adenosinergic receptor modulates oxygen-induced augmentation of murine lung injury.

Authors:  Neil R Aggarwal; Franco R D'Alessio; Yoshiki Eto; Eric Chau; Claudia Avalos; Adam T Waickman; Brian T Garibaldi; Jason R Mock; Daniel C Files; Venkataramana Sidhaye; Vsevolod Y Polotsky; Jonathan Powell; Maureen Horton; Landon S King
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

8.  Interferon-γ: Promising therapeutic target in atherosclerosis.

Authors:  Joe We Moss; Dipak P Ramji
Journal:  World J Exp Med       Date:  2015-08-20

Review 9.  Atherosclerosis and interferon-γ: new insights and therapeutic targets.

Authors:  Iryna Voloshyna; Michael J Littlefield; Allison B Reiss
Journal:  Trends Cardiovasc Med       Date:  2013-08-02       Impact factor: 6.677

10.  Adenosine receptor antagonists effect on plasma-enhanced killing.

Authors:  Gustavo Bauzá; Rituparna Moitra; Daniel Remick
Journal:  Shock       Date:  2014-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.